| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine manufacturers
- Eciruciclib
-
- $48.00
-
2026-08-08
- CAS:1868086-40-1
- Purity: 99.73%
- Supply Ability: 10g
|
| | N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine Basic information |
| Product Name: | N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine | | Synonyms: | N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine;2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[2-methyl-3-(1-methylethyl)-2H-indazol-5-yl]-;inhibit,CDK,Cyclin dependent kinase,Eciruciclib,Inhibitor;N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine;Eciruciclib;N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[2-methyl-3-(1-methylethyl)-2H-indazol-5-yl]-2-pyrimidinamine (ACI) | | CAS: | 1868086-40-1 | | MF: | C27H33FN8 | | MW: | 488.6 | | EINECS: | | | Product Categories: | | | Mol File: | 1868086-40-1.mol | ![N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine Structure](CAS/20200611/GIF/1868086-40-1.gif) |
| | N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine Chemical Properties |
| Boiling point | 682.6±65.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 7.69±0.10(Predicted) | | form | Solid | | color | White to light yellow |
| | N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine Usage And Synthesis |
| Uses | Eciruciclib is an antineoplastic and potent cyclin dependent kinase (CDK) inhibitor[1]. | | References | [1] WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022. |
| | N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-
fluoro-4-[2-methyl-3-(propan-2-yl)-2H-indazol-5-yl]
pyrimidin-2-amine Preparation Products And Raw materials |
|